Integral Derivatives Cut Mrk (MRK) Stake By $2.90 Million; Shorts at Casi Pharmaceuticals (CASI) Raised By 19.72%

January 5, 2018 - By Richard Conner

Casi Pharmaceuticals Incorporated (NASDAQ:CASI) had an increase of 19.72% in short interest. CASI’s SI was 745,400 shares in January as released by FINRA. Its up 19.72% from 622,600 shares previously. With 458,200 avg volume, 2 days are for Casi Pharmaceuticals Incorporated (NASDAQ:CASI)’s short sellers to cover CASI’s short positions. The SI to Casi Pharmaceuticals Incorporated’s float is 2.06%. The stock decreased 0.44% or $0.02 during the last trading session, reaching $3.37. About 67,053 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has declined 17.65% since January 5, 2017 and is downtrending. It has underperformed by 34.35% the S&P500.

Integral Derivatives Llc decreased Mrk (MRK) stake by 84.99% reported in 2017Q3 SEC filing. Integral Derivatives Llc sold 45,387 shares as Mrk (MRK)’s stock declined 2.46%. The Integral Derivatives Llc holds 8,013 shares with $513,000 value, down from 53,400 last quarter. Mrk now has $154.60B valuation. The stock decreased 0.53% or $0.31 during the last trading session, reaching $56.74. About 4.05 million shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 16.86% since January 5, 2017 and is uptrending. It has outperformed by 0.16% the S&P500.

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 4 analyst reports since October 29, 2015 according to SRatingsIntel. H.C. Wainwright initiated CASI Pharmaceuticals, Inc. (NASDAQ:CASI) on Thursday, October 29 with “Buy” rating. The firm has “Buy” rating by Maxim Group given on Monday, August 14. As per Thursday, September 22, the company rating was initiated by Maxim Group.

Investors sentiment decreased to 1.14 in 2017 Q3. Its down 0.53, from 1.67 in 2017Q2. It fall, as 3 investors sold CASI Pharmaceuticals, Inc. shares while 4 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.39 million shares or 4.17% more from 2.29 million shares in 2017Q2 were reported. 291,106 are held by Blackrock. Raymond James Financial Services Advsr, Florida-based fund reported 55,135 shares. Morgan Stanley, a New York-based fund reported 1,157 shares. Geode Management Limited Liability Corporation has invested 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Wellington Shields And Company Lc has 0.29% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 489,984 shares. Financial Bank Of America De holds 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 1,144 shares. Focused Wealth Mngmt reported 45 shares stake. Guggenheim Limited Company reported 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Renaissance Limited Liability Corp invested in 112,900 shares. Wellington Shields Capital Management Llc owns 725,348 shares or 0.17% of their US portfolio. Moors & Cabot owns 26,053 shares. Manatuck Hill Prtnrs Ltd invested in 15,090 shares or 0.01% of the stock. Northern Trust Corp reported 31,034 shares. Royal Comml Bank Of Canada, a Ontario – Canada-based fund reported 17,572 shares. Jpmorgan Chase Company stated it has 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI).

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $218.95 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

Integral Derivatives Llc increased Lmt (Put) (NYSE:LMT) stake by 1,200 shares to 4,000 valued at $1.24M in 2017Q3. It also upped Nvda (Put) (NASDAQ:NVDA) stake by 109,800 shares and now owns 216,200 shares. Unh (Call) (NYSE:UNH) was raised too.

Investors sentiment decreased to 1.06 in 2017 Q3. Its down 0.01, from 1.07 in 2017Q2. It turned negative, as 46 investors sold MRK shares while 619 reduced holdings. 106 funds opened positions while 598 raised stakes. 1.96 billion shares or 0.47% more from 1.95 billion shares in 2017Q2 were reported. Sector Pension Inv Board stated it has 842,705 shares or 0.23% of all its holdings. Davis R M has invested 0.7% in Merck & Co., Inc. (NYSE:MRK). Manning And Napier Ltd invested 0.25% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Cadence Management Limited Liability has invested 0.82% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Rhode Island-based Coastline Co has invested 0.68% in Merck & Co., Inc. (NYSE:MRK). Whittier Tru Comm stated it has 0.66% in Merck & Co., Inc. (NYSE:MRK). Kistler reported 45,409 shares. Moreover, Cipher Cap Ltd Partnership has 0.17% invested in Merck & Co., Inc. (NYSE:MRK) for 34,426 shares. Buckhead Capital Mgmt Ltd Liability Co invested in 12,857 shares. Amica Mutual Ins Com reported 0.87% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Meristem Ltd Liability Partnership holds 0.55% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 21,499 shares. State Street reported 117.82 million shares. Asset Inc, Florida-based fund reported 3,447 shares. Court Place Advisors Lc has invested 0.81% in Merck & Co., Inc. (NYSE:MRK). Natixis holds 0.43% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 729,760 shares.